| 
 | Compound Information | SONAR Target prediction |  | Name: | Vitamin D3 |  | Unique Identifier: | LAT006B10 |  | MolClass: | Checkout models in ver1.5 and ver1.0 |  | Molecular Formula: | C27H44O |  | Molecular Weight: | 340.288 g/mol |  | X log p: | 5.47  (online calculus) |  | Lipinksi Failures | 1 |  | TPSA | 0 |  | Hydrogen Bond Donor Count: | 0 |  | Hydrogen Bond Acceptors Count: | 1 |  | Rotatable Bond Count: | 6 |  | Canonical Smiles: | CC(C)CCCC(C)C1CCC2C(CCCC12C)=CC=C1CC(O)CCC1=C |  | Generic_name: | Calcidiol |  | Chemical_iupac_name: | 6-[4-[2-(5-hydroxy-2-methylidene-cyclohexylidene)ethylidene]-7a-methyl-2,3,3a,5,6,7- hexahydro-1H-inden-1-yl]-2-methyl-heptan-2-ol
 |  | Drug_type: | Approved Drug |  | Pharmgkb_id: | PA452501 |  | Kegg_compound_id: | C01561 |  | Drugbank_id: | APRD00428 |  | H2o_solubility: | Insoluble |  | Logp: | 5.785 |  | Cas_registry_number: | 19356-17-3 |  | Drug_category: | Antihypocalcemic Agents; Antihypoparathyroid Agents; Vitamins (Vitamin D); ATC:A11CC06
 |  | Indication: | Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the
 management of hypocalcemia and renal osteodystrophy in patients with chronic renal
 failure undergoing dialysis. Also used in conjunction with calcium in the management
 and prevention of primary or corticosteroid-induced osteoporosis.
 |  | Pharmacology: | Calcidiol is a form of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and
 phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The
 classical manifestations of vitamin D deficiency is rickets, which is seen in
 children and results in bony deformaties including bowed long bones. Deficiency in
 adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect
 impaired mineralization of newly synthesized bone matrix, and usually result from a
 combination of inadequate exposure to sunlight and decreased dietary intake of
 vitamin D. Common causes of vitamin D deficiency include genetic defects in the
 vitamin D receptor, severe liver or kidney disease, and insufficient exposure to
 sunlight. Vitamin D plays an important role in maintaining calcium balance and in
 the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of
 calcium, increases intestinal absorption of calcium and phosphorus, and increases
 calcium and phosphorus mobilization from bone to plasma.
 |  | Mechanism_of_action: | Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular
 receptors that then function as transcription factors to modulate gene expression.
 Like the receptors for other steroid hormones and thyroid hormones, the vitamin D
 receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a
 complex with another intracellular receptor, the retinoid-X receptor, and that
 heterodimer is what binds to DNA. In most cases studied, the effect is to activate
 transcription, but situations are also known in which vitamin D suppresses
 transcription. Calcitriol increases the serum calcium concentrations by: increasing
 GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and
 increasing distal renal tubular reabsorption of calcium. Calcitriol appears to
 promote intestinal absorption of calcium through binding to the vitamin D receptor
 in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through
 formation of a calcium-binding protein.
 |  | Organisms_affected: | Humans and other mammals | 
 
 
	
		| Species: | 4932 |  
		| Condition: | pdr24h |  
		| Replicates: | 2 |  
		| Raw OD Value: r im | 0.6252±0.00183848 |  
		| Normalized OD Score: sc h | 0.9044±0.0184434 |  
		| Z-Score: | -4.0189±0.905002 |  
		| p-Value: | 0.000365354 |  
		| Z-Factor: | -0.457807 |  
		| Fitness Defect: | 7.9146 |  
		| Bioactivity Statement: | Active |  | | Experimental Conditions |  |  | Library: | LATCA |  | Plate Number and Position: | 6|B10 |  | Drug Concentration: | 50.00 nM |  | OD Absorbance: | 600 nm |  | Robot Temperature: | 27.10 Celcius |  | Date: | 2007-03-08 YYYY-MM-DD |  | Plate CH Control (+): | 0.040925±0.00232 |  | Plate DMSO Control (-): | 0.659375±0.01975 |  | Plate Z-Factor: | 0.9091 | 
 |  png ps
 pdf
 | 
 
 
	
		| 5280447 | (6R)-6-[(1R,4E,7aS)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidene-cyclohexylidene]ethylidene]-7a-methyl-2,3,3a ,5,6,7-hexahydro-1H-inden-1-yl]-2-methyl-heptan-2-ol
 |  
		| 5280795 | (1S,3Z)-3-[(2E)-2-[(1R,3aR,7aS)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4 -ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
 |  
		| 5282368 | (6R)-6-[(1R,4E,7aS)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidene-cyclohexylidene]ethylidene]-7a-methyl-2,3,3a ,5,6,7-hexahydro-1H-inden-1-yl]-2-methyl-heptan-2-ol hydrate
 |  
		| 5283675 | (1S,3Z)-3-[(2E)-2-[(1R,3aR,7aS)-7a-methyl-1-[(2R)-6-methylhept-5-en-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inde n-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
 |  
		| 5283710 | (1R,3Z)-3-[(2E)-2-[(1R,3aR,7aS)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4 -ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
 |  
		| 5283711 | (1S,3Z)-3-[(2E)-2-[(1R,3aR,7aS)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4 -ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
 |  
 | internal high similarity DBLink  | Rows returned: 1 |  | 
 
 | active | Cluster 5423 | Additional Members: 4 | Rows returned: 0 |  | 
 
 |